Breast Surgeon Articles & Analysis
39 news found
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announces entry into a sponsored research agreement with Stanford School of Medicine and the appointment of Frederick M. Dirbas, MD, Associate Professor of Surgery, Division of Surgical Oncology, Stanford School of Medicine ...
Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...
LATTICE MEDICAL, announces the closing of a second round of financing of 8 million euros. This round was led by the historical funds Finovam Gestion, Nord France Amorçage and WiSEED alongside the Captech Santé fund. The European Commission, via its EIC Fund, and Santelys are co-investing. The financing round is completed by non-dilutive financing, in the form of a grant and debt ...
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre ...
The new medical imaging technology will be used under the direction of Michele Carpenter, MD, a breast surgeon who performs breast conservation and other surgeries at Pavilion Surgery Center. ...
QView Medical is pleased to announce FDA approval for QVCAD to be used with the GE Invenia™ ABUS in breast screening for asymptomatic dense breasted women whose mammogram was negative. ...
OnLume’s imaging device will seamlessly integrate into the clinical workflow with a small physical footprint, an easy-to-use interface and compatibility with ambient lighting in the operating room. As part of this grant, breast surgeon collaborators will use OnLume’s imaging device for intraoperative visualization and assessment of small lymphatic ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL. The results of the study ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 DCIS patients demonstrating the clinical utility of DCISionRT? was selected for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results evaluating the association of DCISionRT, a predictive DCIS ...
The new information was presented in an oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd Annual Meeting, held on April 6 - 10, 2022 at Wynn Las Vegas, NV. ...
The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure. Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors including BlueStone Venture Partners. Alejandro Sanchez, Managing Director of Evidity Health Capital, will be joining PreludeDx’s Board of ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing DCISionRT? and its integrated Residual Risk subtype (RRt) with traditional clinicopathology features at the 39th Annual Miami Breast Cancer Conference (MBCC), being held on March 3 – 6, 2022 at the Fontainebleau Miami ...
This pioneering technology allows surgeons to examine an excised tissue sample and identify areas of concern to support ‘real-time’ margin assessment during a ...
Fine, MD and Michael Berry, MD, leading breast surgeons based out of the Margaret West Comprehensive Breast Center in Germantown, Tennessee. ...
Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the publication of SweDCIS randomized clinical trial data in the Special Issue: Updates on Breast Cancer edition of Cancers. The randomized study demonstrates that the DCISionRT test predicts radiation benefit for reducing 10-year local invasive breast cancer risk. ...
Trial start-up activities are already underway, with world-class sites and a number of the nation’s leading breast surgeons identified to participate in Perimeter’s pivotal study, which we anticipate initiating in mid-November at our first site at West Cancer Center’s Breast Center in Germantown, Tennessee under the direction of ...
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in ...
Study Demonstrate Superiority of VeraForm® Marker Over Clips For Tumor Bed Delineation Accuracy San Francisco CA, October 28, 2021- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an independent study at this week’s ASTRO conference in Chicago and the American ...